IL1B and neoplasm: However, a long‐term clinical trial presented that the addition of celecoxib was proposed cannot the improve overall survival for patients who received tumor resection.[45] We proposed that developing a direct target focusing on surgical damage‐induced inflammation could potentially enhance long‐term survival in osteosarcoma patients after surgeries.[46] In our study, the lungs of IL‐1β−/− mice displayed reduced inflammation and infiltration of Gr‐1+ myeloid cells after surgery, rendering them resistant to tumor cell colonization.